Medical imaging company SpectraWAVE, Inc. has raised an oversubscribed $50 million Series B funding to support commercial expansion and product additions for the company’s HyperVue imaging system.

HyperVue technology combines DeepOCT and near-IR spectroscopy into an AI-driven workflow and image analysis offering. The platform was developed for intravascular imaging applications such as coronary stenting procedures, plaque morphology, and future adverse event risk, among others.

Additionally, according to SpectraWAVE CEO Eman Namati, the company is currently in development on a wire-free physiology software addition for the HyperVue. The software would allow physicians to rapidly assess pressure drops in a patient’s coronary arteries by using the product's hardware, the company said.

Johnson & Johnson Innovation led the funding round.

---

There are 394 suppliers of Software in the Photonics Marketplace.

---